- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07943052
Intrauterine Misoprostol in Cesarean Delivery: Effect on Postpartum Hemorrhage
Evaluation of the Efficacy of Intrauterine Misoprostol Administration on Postpartum Hemorrhage in Cesarean Operations
This prospective, randomized, controlled, two-arm study evaluates whether adding intrauterine (uterine cornual) misoprostol 400 mcg to standard oxytocin reduces postpartum blood loss in term women undergoing elective cesarean delivery. Participants are randomized 1:1 to standard oxytocin alone or standard oxytocin plus misoprostol. The primary outcome is the change in hemoglobin and hematocrit from preoperative values to 6, 24 and 48 hours after surgery.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
A total of 142 women (71 per group) will be enrolled. The study group receives standard oxytocin plus a single 400 mcg dose of misoprostol placed in the uterine cornual region after placental delivery; the control group receives standard oxytocin only. Hemoglobin and hematocrit are measured before surgery and at 6, 24 and 48 hours afterwards, and participants are seen on postoperative day 10 for late complications and adverse events. The surgical team is not masked; participants are not informed of their allocation. An interim safety analysis is planned after 50 participants.
Studietype
Registrering (Antatt)
Fase
- Fase 4
Kontakter og plasseringer
Studiekontakt
- Navn: Halil Gümüş, MD
- Telefonnummer: +90 537 673 47 49
- E-post: dr.halil.gumusrc@gmail.com
Studiesteder
-
-
-
Istanbul, Tyrkia (Türkiye)
- Bagcilar Training and Research Hospital, Department of Obstetrics and Gynecology
-
Ta kontakt med:
- Halil Gümüş, MD
- Telefonnummer: +90 537 673 47 49
- E-post: dr.halil.gumusrc@gmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age 18-45 years
- Term pregnancy (37 weeks or more)
- Elective cesarean section planned
- ASA I-II
- Written informed consent signed
Exclusion Criteria:
- History of coagulopathy or active bleeding disorder
- Anticoagulant use
- Hemoglobin < 10 g/dL
- Active thromboembolic disease
- Severe hepatic failure
- BMI > 35 kg/m2
- Type 1 diabetes with diabetic nephropathy
- Chronic hypertension
- Gestational hypertension, preeclampsia, eclampsia or HELLP syndrome
- Placenta previa, placental abruption or placental pathology with high bleeding risk
- Multiple pregnancy
- Uterine anomalies
- Intrauterine fetal death
- Epilepsy (diagnosis or history)
- Active malignancy
- Known hypersensitivity to prostaglandins
- Refusal or withdrawal of consent
- Emergency-indicated cesarean sections (including those planned as elective but performed for fetal distress, uterine rupture or other emergency indications)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Misoprostol plus standard oxytocin
Standard oxytocin plus a single 400 mcg dose of misoprostol placed in the uterine cornual region after delivery of the placenta during elective cesarean delivery. |
Misoprostol 400 mcg (2 x 200 mcg tablets), single dose placed in the uterine cornual region after delivery of the placenta, in addition to standard oxytocin. Standard oxytocin administered after delivery of the baby according to routine clinical practice (standard of care in both arms). |
|
Aktiv komparator: Standard oxytocin
Standard oxytocin only, according to routine clinical practice, during elective cesarean delivery. |
Standard oxytocin administered after delivery of the baby according to routine clinical practice (standard of care in both arms). |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in hemoglobin from preoperative value to postoperative 6, 24 and 48 hours
Tidsramme: Preoperative, and 6, 24 and 48 hours after surgery
|
Hemoglobin (g/dL) measured before surgery and at 6, 24 and 48 hours after surgery; change from the preoperative value is compared between groups. |
Preoperative, and 6, 24 and 48 hours after surgery
|
|
Change in hematocrit from preoperative value to postoperative 6, 24 and 48 hours
Tidsramme: Preoperative, and 6, 24 and 48 hours after surgery
|
Hematocrit (%) measured before surgery and at 6, 24 and 48 hours after surgery; change from the preoperative value is compared between groups. |
Preoperative, and 6, 24 and 48 hours after surgery
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Need for blood transfusion
Tidsramme: From surgery until hospital discharge, up to 48 hours
|
Proportion of participants requiring blood transfusion after surgery. |
From surgery until hospital discharge, up to 48 hours
|
|
Need for additional uterotonic or hemostatic intervention
Tidsramme: During surgery and until hospital discharge, up to 48 hours
|
Proportion of participants requiring additional uterotonic agents or other hemostatic interventions. |
During surgery and until hospital discharge, up to 48 hours
|
|
Late postoperative complications and readmission
Tidsramme: Up to postoperative day 10
|
Late complications and hospital readmission assessed at the postoperative day 10 visit. |
Up to postoperative day 10
|
|
Misoprostol-related adverse events
Tidsramme: Up to postoperative day 10
|
Adverse events potentially related to misoprostol (e.g., fever, shivering, nausea, vomiting, diarrhea) recorded in both groups. |
Up to postoperative day 10
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Cem Yener, MD, Associate Professor, Bagcilar Training and Research Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Patologiske prosesser
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Obstetriske arbeidskomplikasjoner
- Graviditetskomplikasjoner
- Blødning
- Puerperale lidelser
- Livmorblødning
- Patologiske tilstander, tegn og symptomer
- Postpartum blødning
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Peptidhormoner
- Peptider
- Aminosyrer, peptider og proteiner
- Fettsyrer
- Lipider
- Biologiske faktorer
- Prostaglandiner, syntetisk
- Prostaglandiner
- Eikosanoider
- Fettsyrer, umettet
- Autacoider
- Betennelsesformidlere
- Hypofysehormoner, bakre
- Hypofysehormoner
- Prostaglandiner E, syntetisk
- Oksytocin
- Misoprostol
Andre studie-ID-numre
- E-66291034-50.04-7274
- 248 (Annen identifikator: Istanbul Medipol University Clinical Research Ethics Committee)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .